KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biocryst Pharmaceuticals (BCRX) Short term Debt (2023 - 2025)

Biocryst Pharmaceuticals (BCRX) has disclosed Short term Debt for 3 consecutive years, with $38.5 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Short term Debt rose 17.69% year-over-year to $38.5 million, compared with a TTM value of $38.5 million through Dec 2025, up 17.69%, and an annual FY2025 reading of $38.5 million, up 17.69% over the prior year.
  • Short term Debt was $38.5 million for Q4 2025 at Biocryst Pharmaceuticals, up from $37.7 million in the prior quarter.
  • Across five years, Short term Debt topped out at $38.5 million in Q4 2025 and bottomed at $23.6 million in Q4 2023.
  • Average Short term Debt over 3 years is $32.3 million, with a median of $33.0 million recorded in 2024.
  • The sharpest move saw Short term Debt skyrocketed 38.66% in 2024, then increased 14.2% in 2025.
  • Year by year, Short term Debt stood at $23.6 million in 2023, then surged by 38.66% to $32.7 million in 2024, then increased by 17.69% to $38.5 million in 2025.
  • Business Quant data shows Short term Debt for BCRX at $38.5 million in Q4 2025, $37.7 million in Q3 2025, and $35.7 million in Q2 2025.